Accendra Health, Inc. (ACH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed financial performance with growth in some areas but declines in others, notably due to the exit from a large commercial payer. While the company has plans for cost management and debt reduction, uncertainties in free cash flow and reliance on older projections for future growth suggest caution. Positive elements like the Sleep Journey program and strategic initiatives are counterbalanced by challenges in diabetes and home respiratory revenue. Overall, the sentiment is balanced, leading to a neutral prediction for short-term stock price movement.
Key Financial Performance
Revenue Reported a decline of 6.8% year-over-year in the first quarter of 2026. Excluding the impact of the large commercial payor exit, growth would have been about 1%. The decline was primarily due to the exit from a large commercial payor.
Sleep Category Revenue Grew over 4% year-over-year, excluding the impact of the large commercial payor exit. Growth was driven by the sleep journey program, which improved revenue per order, reduced patient attrition, and increased therapy adherence rates.
Home Respiratory Revenue Fell about 4% year-over-year, excluding the impact of the large commercial payor exit. No specific reasons for the decline were mentioned.
Diabetes Revenue Slightly declined year-over-year as growth in insulin pumps did not offset a drop in CGMs (Continuous Glucose Monitors).
Adjusted EBITDA Reported at $58 million for the first quarter of 2026, in line with expectations. Year-over-year decline was due to lower collection rates, inflationary product cost increases, higher health benefit expenses, and elevated SG&A expenses, partially offset by cost savings efforts.
Cash Proceeds from Equipment Sale Generated $82 million in cash proceeds from the sale of patient service equipment related to the large commercial payor exit, resulting in a book gain of $52 million. This was a one-time transaction.
Net Debt Remained flat at $1.77 billion compared to the end of 2025. The company maintained $337 million in cash and $195 million in available credit facility capacity.
Free Cash Flow Slightly negative in the first quarter of 2026 due to seasonal softness, extraordinary payments of $19 million to the IRS for tax matters, and $22 million for previously accrued expenses related to the P&HS divestiture.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Sleep Journey Program: Continues to deliver anticipated results with strong year-over-year growth in the sleep supplies category. It drives higher revenue per order, lower patient attrition, and better patient outcomes through higher therapy adherence rates.
Sleep Center of Excellence: A new initiative designed to centralize and standardize patient interactions for PAP therapy. It aims to improve patient satisfaction, loyalty, and provider confidence, with a successful pilot in Q1 and a nationwide launch in Q2.
Exclusive Multiyear Extension with Largest Commercial Payor: Secured an exclusive multiyear extension for soft goods, providing business certainty in the years ahead.
Diversified Commercial Payor Portfolio: Maintains a diversified portfolio with no major renewals on the horizon, ensuring stability.
Transition from Owens & Minor: Successfully completed transition services and separation activities, now operating as a fully independent company.
Exit from Large Commercial Payor: Substantially completed the exit, including selling equipment and transitioning personnel to another industry player, minimizing costs and ensuring continuity of care.
Capital Structure Optimization: Announced a comprehensive balance sheet optimization transaction to reduce debt, extend maturities, and enhance financial flexibility.
Streamlining Business Operations: Focused on centralization, standardization, and automation to drive growth and reduce costs while enhancing patient experience.
Focus on Home-Based Care: Transitioned into a leaner, higher-margin business with nearly 50% gross margins and double-digit EBITDA margins.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Transition from Owens & Minor: The transition services and separation activities from Owens & Minor are on track, but the process of becoming a fully independent company involves risks related to operational disruptions and the need to rationalize corporate infrastructure.
Exit from Large Commercial Payor: The exit from a large commercial payor, while managed smoothly, involved selling equipment and transitioning personnel, which could have financial and operational impacts. Additionally, exiting a major customer relationship poses risks to revenue stability.
Regulatory Compliance: The company supports government efforts to eliminate fraud and waste, but compliance with competitive bidding programs and other regulations could pose challenges.
Cost Pressures: The company faces inflationary product cost increases, higher health benefit expenses, and lower collection rates, which are impacting profitability.
Debt and Capital Structure: The company is undergoing a balance sheet optimization process to address debt maturities and improve liquidity. However, higher interest expenses from refinancing could strain financial performance.
Revenue Growth Challenges: Revenue declined by 6.8% in the quarter, with growth rates not meeting expectations in some categories. This poses a challenge to achieving financial targets.
Operational Efficiency: Efforts to streamline operations through centralization, standardization, and automation are ongoing, but achieving these efficiencies involves execution risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Transition services and separation activities: Accendra Health is on track to fully function as an independent company from Owens & Minor, focusing on growth in the home-based care space.
Exit from large commercial payor: The company has substantially completed the exit from a large commercial payor, ensuring continuity of care for patients and minimizing transition costs. This includes selling equipment and transitioning personnel to another industry player.
Payor agreements: Accendra Health has secured a multiyear extension with its largest commercial payor for soft goods, providing business certainty for the years ahead. The company maintains a diversified commercial payor portfolio with no major renewals on the horizon.
Sleep therapy initiatives: The sleep journey program and the new Sleep Center of Excellence are expected to drive growth in the sleep category by improving patient adherence, enhancing patient experience, and increasing provider confidence.
Capital structure optimization: The company announced a balance sheet optimization transaction to strengthen its financial position by paying off 2027 maturities, reducing total debt, and extending maturities, providing financial and strategic flexibility.
Revenue growth: Revenue growth is expected to improve throughout 2026, with stronger performance anticipated in the latter half of the year. Categories like sleep, urology, and ostomy are expected to drive growth.
Adjusted EBITDA: At least 65% of adjusted EBITDA is projected to come in the third and fourth quarters of 2026, supported by revenue growth, better collection rates, and cost savings.
Interest expense: Annualized cash interest is expected to increase by approximately $40 million due to refinancing activities, with half of the impact occurring in the second half of 2026.
Capital structure: The company plans to extend its debt maturity runway to approximately 5.5 years, ensuring liquidity and financial flexibility for future operations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the expectations for free cash flow post-restructuring, particularly for 2026 and beyond?
A:Jonathan Leon stated that any generated cash flow will be used for debt reduction. However, exact numbers are uncertain until the financing is completed, likely in the next month or two. Approximately half of the $40 million increased interest expense will impact this year, but it is still expected to be a good cash flow year.
Q:What is the company's position and outlook in the diabetes market?
A:Edward Pesicka highlighted growth in insulin pumps and unit volume growth in CGM, though there was price compression due to the mix between DME and pharmacy. He emphasized the higher adherence rates in the DME channel compared to the pharmacy channel and the company's focus on educating patients and providers about the benefits of the DME channel.
Q:Should the company’s projected 4% revenue growth and 5% EBITDA growth for 2027 be considered a normalized growth rate?
A:Jonathan Leon cautioned against relying too heavily on the 2027 projections, as they were based on older data. However, he acknowledged that the growth rates are a decent proxy for the business's run rate going forward. He also noted that some cash flow will be reinvested into the business in 2027.
Q:What is the status and impact of the Sleep Journey and Sleep Center of Excellence initiatives?
A:Edward Pesicka and Perry Bernocchi explained that the Sleep Journey has been in progress for over a year, showing single-digit percentage improvements in adherence rates and increased average order basket size. The Sleep Center of Excellence is being rolled out, currently live in three markets, with full implementation expected by the beginning of Q4. Early results show improved speed from referral to therapy initiation and other positive metrics.
Q:What drove the results this quarter and what is expected for the rest of the year across various product categories?
A:Jonathan Leon noted consistent dynamics across categories, with growth in ostomy, urology, and sleep businesses, while diabetes (particularly CGM) and home respiratory underperformed. Optum's onboarding is expected to ramp through 2026, and debt refinancing is anticipated to close by mid to late June.
Q:What is the trajectory of SG&A expenses for the year?
A:Jonathan Leon and Edward Pesicka indicated that SG&A cost reductions remain a focus, with additional benefits expected for the rest of the year due to cost removal related to a large customer. The Q1 run rate is a reasonable starting point, but further improvements are anticipated.
Q:What is the status of smaller capitated agreements and their impact on margins?
A:Edward Pesicka and Perry Bernocchi stated that remaining capitated agreements are small and efficient, providing positive yields. The company is pursuing additional smaller capitated agreements, which are seen as opportunities in a dynamic market.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for free cash flow expectations for 2026 and beyond, citing the need for more time to finalize forecasts. Similarly, they cautioned against relying too heavily on 2027 projections, as they were based on older data and would be updated later in the year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Center Excellence
Conference today
Excellence capture
Excellence expert
Excellence satisfaction
Health PHS
Health home
Health result
Instructions conference
Matters statement
Medicare government
Minor Page
Minor focus
Minor track
National Parent
Officer today
PAP therapy
PHS consumption
Page slide
Parent slide
Parrish Vice
Sleep Center
Slide
effort
exit
experience patient
extension
industry player
journey Sleep
optimization transaction
outcome
payor
payors
portfolio
quality
track record
ACH Transcript
Accendra Health, Inc. (ACH) Q1 2026 Earnings Call Transcript
Unknown5-11
The earnings call reveals mixed financial performance with growth in some areas but declines in others, notably due to the exit from a large commercial payer. While the company has plans for cost management and debt reduction, uncertainties in free cash flow and reliance on older projections for future growth suggest caution. Positive elements like the Sleep Journey program and strategic initiatives are counterbalanced by challenges in diabetes and home respiratory revenue. Overall, the sentiment is balanced, leading to a neutral prediction for short-term stock price movement.
Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call presents a mixed picture: while there is a focus on debt reduction and technology investments, there are concerns about inflation outpacing pricing growth and uncertainties in revenue replacement from Optum. The Q&A reveals a cautious outlook with some positive elements like expected improvements in collection rates and diversified growth in therapy categories. However, the lack of clear guidance on CapEx and the absence of a specific update on competitive dynamics temper the overall sentiment, leading to a neutral outlook.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
